Skip to content

Exploring the Efficacy and Safety of Tofacitinib in the Treatment of Rosacea

Exploring the Efficacy and Safety of Tofacitinib in the Treatment of Rosacea

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096227
Enrollment
Unknown
Registered
2025-01-20
Start date
2025-01-20
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rosacea

Interventions

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age>= 18 years; 2.Diagnosed with rosacea according to the Chinese Rosacea Diagnosis and Treatment Guidelines (2021 Edition); 3.Treatment includes tofacitinib; 4.Blood, liver, and kidney function tests are normal; 5.Have a history of more than 2 weeks of ineffective traditional oral and topical medication treatment; 6.Have at least two follow-up visits since starting treatment.

Exclusion criteria

Exclusion criteria: 1.patients with active infections (such as hepatitis B, tuberculosis, HIV); 2.patients with uncontrolled or severe systemic diseases or malignant tumors; 3.pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
VISIA red area value;symptom score;

Secondary

MeasureTime frame
DLQI;RosQol;

Countries

China

Contacts

Public ContactHUANG KUN

The First Affiliated Hospital of Chongqing Medical University

feelingkun@126.com+86 23 8901 1876

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026